NEW YORK, Jan. 23, 2017 /PRNewswire/ -- Delcath
Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company
focused on the treatment of primary and metastatic liver cancers,
today announced that Jennifer K.
Simpson, Ph.D., MSN, CRNP, President and Chief Executive
Officer of Delcath will be a featured presenter at the NobleCon13 -
Noble Capital Markets' Thirteenth Annual Investor Conference at the
Boca Raton Resort & Club in Boca
Raton, Florida, on Tuesday, January
31, 2017 at 10:30 am Eastern Standard
Time.
A high-definition, video webcast of Delcath's presentation will
be available at
http://noble.mediasite.com/mediasite/Play/b9ba93421f9245eb8a86b42ab119a0161d.
A Microsoft SilverLight viewer (a free download from the
presentation link) is required to participate. The webcast and
presentation will be archived on the Company's website at
www.delcath.com and on the Noble websites,
www.noblecapitalmarkets.com, or www.nobleconference.com, for 90
days following the event. Management will also be available for
one-on-one meetings on January 30 and
31, 2017.
About Noble Capital Markets, Inc.
Noble Capital
Markets, established in 1984, is an equity-research driven,
full-service, investment & merchant banking boutique focused on
the healthcare, media & entertainment, technology and natural
resources sectors. The company has offices in Boca Raton, New
York and Boston. In
addition to NobleCon - the annual multi-sector investor conference
and the Media, Finance & Investor Conference, produced in
partnership with the National Association of Broadcasters (NAB) and
held each spring in Las Vegas,
throughout the year Noble hosts numerous "non-deal" corporate road
shows across the United States and
Canada. Members: FINRA, SIPC,
MSRB. www.noblecapitalmarkets.com
About Delcath Systems
Delcath Systems, Inc. is
an interventional oncology Company focused on the treatment of
primary and metastatic liver cancers. Our investigational
product—Melphalan Hydrochloride for Injection for use with the
Delcath Hepatic Delivery System (Melphalan/HDS) —is designed to
administer high-dose chemotherapy to the liver while controlling
systemic exposure and associated side effects. We have commenced a
global Phase 3 FOCUS clinical trial for Patients with Hepatic
Dominant Ocular Melanoma (OM) and a global Phase 2 clinical trial
in Europe and the U.S. to investigate the Melphalan/HDS
system for the treatment of primary liver cancer (HCC) and
intrahepatic cholangiocarcinoma (ICC). Melphalan/HDS has not been
approved by the U.S. Food & Drug Administration (FDA) for sale
in the U.S. In Europe, our system has been commercially
available since 2012 under the trade name Delcath Hepatic
CHEMOSAT® Delivery System for Melphalan (CHEMOSAT),
where it has been used at major medical centers to treat a wide
range of cancers of the liver.
Forward Looking Statements:
Private Securities
Litigation Reform Act of 1995 provides a safe harbor for
forward-looking statements made by the Company or on its behalf.
This news release contains forward-looking statements, which are
subject to certain risks and uncertainties that can cause actual
results to differ materially from those described. Factors that may
cause such differences include, but are not limited to,
uncertainties relating to: our ability to repay and comply
with the obligations under our senior secured convertible notes,
the timing and results of the Company's clinical trials
including without limitation the OM, HCC, and ICC clinical trial
programs, timely enrollment and treatment of patients in the global
Phase 3 FOCUS Clinical Trial for Patients with Hepatic Dominant
Ocular Melanoma and the global Phase 2 HCC and ICC clinical trials,
IRB or ethics committee clearance of the Phase 2 HCC/ICC and/or
Phase 3 OM protocols from participating sites and the timing of
site activation and subject enrollment in each trial, the impact,
if any, of publication of the Phase 3 trial manuscript to support
the Company's efforts, the impact of the presentations at major
medical conferences and future clinical results consistent with the
data presented, the impact, if any, of ZE reimbursement on
potential CHEMOSAT product use and sales in Germany, clinical adoption, use and resulting
sales, if any, for the CHEMOSAT system to deliver and filter
melphalan in Europe, the Company's
ability to successfully commercialize the CHEMOSAT/Melphalan HDS
system and the potential of the CHEMOSAT/Melphalan HDS system as a
treatment for patients with primary and metastatic disease in the
liver, our ability to obtain reimbursement for the CHEMOSAT system
in various markets, the Company's ability to satisfy the remaining
requirements of the FDA's Complete Response Letter and provide the
same in a timely manner, approval of the current or future
Melphalan HDS/CHEMOSAT system for delivery and filtration of
melphalan for various indications in the U.S. and/or in foreign
markets, actions by the FDA or other foreign regulatory agencies,
the Company's ability to successfully enter into strategic
partnership and distribution arrangements in foreign markets and
the timing and revenue, if any, of the same, uncertainties relating
to the timing and results of research and development projects, our
ability to maintain NASDAQ listing, and uncertainties regarding the
Company's ability to obtain financial and other resources for any
research, development, clinical trials and commercialization
activities. These factors, and others, are discussed from time to
time in our filings with the Securities and Exchange Commission.
You should not place undue reliance on these forward-looking
statements, which speak only as of the date they are made. We
undertake no obligation to publicly update or revise these
forward-looking statements to reflect events or circumstances after
the date they are made.
Contact Information:
Investor Contact:
Anne Marie Fields
LHA
212-838-3777
afields@lhai.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/delcath-systems-to-present-at-the-noblecon13---noble-capital-markets-thirteenth-annual-investor-conference-on-january-31-2017-300394539.html
SOURCE Delcath Systems, Inc.